<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002792</url>
  </required_header>
  <id_info>
    <org_study_id>1032.01</org_study_id>
    <secondary_id>FHCRC-1032.01</secondary_id>
    <secondary_id>NCI-H96-0929</secondary_id>
    <secondary_id>CDR0000064859</secondary_id>
    <nct_id>NCT00002792</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders</brief_title>
  <official_title>ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining bone marrow or peripheral stem cell transplantation with&#xD;
      chemotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus either&#xD;
      bone marrow or peripheral stem cell transplantation in treating patients with&#xD;
      myeloproliferative disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess disease free survival in patients with idiopathic myelofibrosis treated with a&#xD;
           preparative busulfan/cyclophosphamide regimen followed by allogeneic bone marrow or&#xD;
           peripheral blood stem cell transplantation.&#xD;
&#xD;
        -  Determine the risk of primary graft failure in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive a preparative regimen consisting of oral busulfan every 6 hours on&#xD;
      days -7 through -4 and cyclophosphamide on days -3 and -2. Patients then receive allogeneic&#xD;
      bone marrow or peripheral blood stem cells on day 0. Patients registered on protocol&#xD;
      FHCRC-1106.00 randomized to stem cell transplant receive unmodified G-CSF-mobilized stem&#xD;
      cells from an HLA-identical donor.&#xD;
&#xD;
      Patients receive cyclosporine/methotrexate or tacrolimus/methotrexate as prophylaxis for&#xD;
      graft-versus-host disease (GVHD). Patients receiving marrow from unrelated donors are&#xD;
      eligible for appropriate GVHD prophylaxis studies.&#xD;
&#xD;
      Patients are followed at 6 and 12 months after transplant.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study over approximately&#xD;
      3.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1996</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Idiopathic myelofibrosis (IMF) with at least 1 poor prognosis characteristic,&#xD;
             including but not limited to:&#xD;
&#xD;
               -  Hemoglobin less than 10 g/dL&#xD;
&#xD;
               -  Platelet count less than 100,000/mm^3&#xD;
&#xD;
               -  Hepatomegaly (i.e., palpable liver edge 5 cm below costal margin)&#xD;
&#xD;
               -  Clinical requirement for splenectomy&#xD;
&#xD;
          -  Other myeloproliferative disorders in an IMF like myelofibrotic state eligible&#xD;
&#xD;
          -  No evidence of leukemic progression, e.g.:&#xD;
&#xD;
               -  Greater than 15% peripheral blood blasts&#xD;
&#xD;
               -  Fever or bone pain of unknown origin&#xD;
&#xD;
               -  Rapidly progressing splenomegaly&#xD;
&#xD;
          -  No other causes for myelofibrosis, such as:&#xD;
&#xD;
               -  Collagen vascular disorder&#xD;
&#xD;
               -  Lymphoma&#xD;
&#xD;
               -  Granulomatous infection&#xD;
&#xD;
               -  Metastatic carcinoma&#xD;
&#xD;
               -  Hairy cell leukemia&#xD;
&#xD;
               -  Myelodysplastic syndrome&#xD;
&#xD;
          -  No active central nervous system disease&#xD;
&#xD;
          -  One of the following donor/patient pairings is required:&#xD;
&#xD;
               -  Donor status:&#xD;
&#xD;
                    -  Genotypic or phenotypic HLA-matched relative&#xD;
&#xD;
                         -  Maximum patient age of 65&#xD;
&#xD;
                    -  One antigen HLA-mismatched relative, HLA-matched unrelated donor, or one&#xD;
                       antigen HLA-mismatched unrelated donor&#xD;
&#xD;
                         -  Maximum patient age of 55&#xD;
&#xD;
          -  Transplant on this protocol allowed for patients registered on protocol FHCRC-1106.00&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  65 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times normal&#xD;
&#xD;
          -  SGPT no greater than 4 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than two times normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 50%&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction at least 50%&#xD;
&#xD;
          -  Cardiac evaluation required if signs or symptoms of coronary artery disease or&#xD;
             congestive heart failure&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  Patients excluded from this protocol are referred to protocol FHCRC-179.05&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Joachim Deeg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol. 1997 Sep;98(4):1010-6. doi: 10.1046/j.1365-2141.1997.3083125.x.</citation>
    <PMID>9326205</PMID>
  </results_reference>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 31, 2010</last_update_submitted>
  <last_update_submitted_qc>March 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2010</last_update_posted>
  <keyword>polycythemia vera</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

